(Q37858523)

24 August 2017

1 reference

title

Lenalidomide: a review of its use in the treatment of relapsed or refractory multiple myeloma (English)

1 reference

24 August 2017

1

Lesley J Scott

1 reference

Katherine A Lyseng-Williamson

24 August 2017

series ordinal

2

object named as

Katherine A Lyseng-Williamson

1 reference

24 August 2017

publication date

1 March 2011

1 reference

24 August 2017

1 reference

24 August 2017

volume

71

1 reference

24 August 2017

issue

5

1 reference

24 August 2017

page(s)

625-649

1 reference

https://scigraph.springernature.com/pub.10.2165/11206420-000000000-00000

24 August 2017

exact match

0 references

cites work

Global cancer statistics, 2002

1 reference

https://api.crossref.org/works/10.2165%2F11206420-000000000-00000

Familial risks and temporal incidence trends of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206420-000000000-00000

Multiple myeloma: charging toward a bright future.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206420-000000000-00000

Autologous hematopoietic stem-cell transplantation for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206420-000000000-00000

Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206420-000000000-00000

Thalidomide and lenalidomide in the treatment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206420-000000000-00000

Immune regulation in multiple myeloma: the host-tumour conflict

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206420-000000000-00000

Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206420-000000000-00000

High expression of BCL3 in human myeloma cells is associated with increased proliferation and inferior prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206420-000000000-00000

Soluble decoy receptor 3 modulates the survival and formation of osteoclasts from multiple myeloma bone disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206420-000000000-00000

International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206420-000000000-00000

The role of novel drugs in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206420-000000000-00000

Thalidomide for treatment of multiple myeloma: 10 years later

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206420-000000000-00000

Advances in the treatment of hematological malignancies: current treatment approaches in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206420-000000000-00000

Lenalidomide mode of action: linking bench and clinical findings

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206420-000000000-00000

Lenalidomide for the treatment of B-cell malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206420-000000000-00000

Mechanism of action of immunomodulatory agents in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206420-000000000-00000

Recent advances of IMiDs in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206420-000000000-00000

Mechanism of action of lenalidomide in hematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206420-000000000-00000

Properties of thalidomide and its analogues: implications for anticancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206420-000000000-00000

Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206420-000000000-00000

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206420-000000000-00000

Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206420-000000000-00000

Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206420-000000000-00000

Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206420-000000000-00000

Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206420-000000000-00000

Tumor cell gene expression changes following short-term in vivo exposure to single agent chemotherapeutics are related to survival in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206420-000000000-00000

Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206420-000000000-00000

Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206420-000000000-00000

Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206420-000000000-00000

Bone markers in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206420-000000000-00000

Lenalidomide plus dexamethasone treatment in Japanese patients with relapsed/refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206420-000000000-00000

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206420-000000000-00000

Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206420-000000000-00000

Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206420-000000000-00000

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206420-000000000-00000

Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206420-000000000-00000

Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206420-000000000-00000

Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206420-000000000-00000

Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high-dose dexamethasone

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206420-000000000-00000

Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206420-000000000-00000

Diagnostic evaluation of t(4;14) in multiple myeloma and evidence for clonal evolution.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206420-000000000-00000

Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206420-000000000-00000

International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206420-000000000-00000

Pathogenesis and treatment of renal failure in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206420-000000000-00000

The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206420-000000000-00000

Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206420-000000000-00000

Recent major improvement in long-term survival of younger patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206420-000000000-00000

The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206420-000000000-00000

Treatment strategies in elderly patients with multiple myeloma: current status

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206420-000000000-00000

Novel therapies in myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206420-000000000-00000

Prognostic factors for multiple myeloma in the era of novel agents

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206420-000000000-00000

Lenalidomide in myelodysplastic syndrome and multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206420-000000000-00000

An update: health economics of managing multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11206420-000000000-00000

Myeloma--new approaches to combined nephrological-haematological management

21 January 2018

1 reference

12 December 2020

Newer therapeutic molecules for multiple myeloma.

1 reference

12 December 2020

Lenalidomide and dexamethasone for the treatment of refractory/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairment

1 reference

12 December 2020

Changes in activatory and inhibitory natural killer (NK) receptors may induce progression to multiple myeloma: implications for tumor evasion of T and NK cells

1 reference

12 December 2020

Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement

1 reference

12 December 2020

Tumor necrosis factor is a survival and proliferation factor for human myeloma cells.

1 reference

12 December 2020

Lenalidomide in combination with dexamethasone: effective regimen in patients with relapsed or refractory multiple myeloma complicated by renal impairment

1 reference

12 December 2020

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

1 reference

12 December 2020

Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force report

1 reference

12 December 2020

10.2165/11206420-000000000-00000

Identifiers

DOI

1 reference

24 August 2017

1 reference